NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379]

Committee Papers

© National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner.

NICE National Institute for Health and Care Excellence

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Idelalisib for treating follicular lymphoma refractory to 2 treatments [ID1379]

Contents:

The following documents are made available to consultees and commentators:

1. **Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)**

2. **Comments on the Appraisal Consultation Document from Gilead**
   a. Company response to the ACD (including additional evidence)
   b. Letter of clinical consensus

3. **Consultee and commentator comments on the Appraisal Consultation Document** from:
   a. Bloodwise
   b. Lymphoma Action
   c. Royal College of Pathologists and the British Society for Haematology

4. **Response to questions from the technical team from experts and the company**
   a. Response from clinical experts
   b. Response from the company

5. **Evidence Review Group critique of company comments on the ACD**

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.

© National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner.